Lovenox Cost-Effectiveness Over Heparin Highlighted In ACC/AHA Guidelines
Executive Summary
The cost-effectiveness of Rhone-Poulenc Rorer's Lovenox relative to unfractionated heparin in the treatment of unstable angina/non-Q-wave myocardial infarction is discussed in the 1999 American College of Cardiology/ American Heart Association practice guidelines.
You may also be interested in...
DuPont's Innohep Anticoagulant Approved With Once-Daily Dosing Regimen
DuPont's low molecular weight heparin Innohep will enter the market as the only treatment with once-daily dosing for all patients with deep vein thrombosis. Other LMWHs have a mix of recommended dosages, which may include once-daily administration.
DuPont's Innohep Anticoagulant Approved With Once-Daily Dosing Regimen
DuPont's low molecular weight heparin Innohep will enter the market as the only treatment with once-daily dosing for all patients with deep vein thrombosis. Other LMWHs have a mix of recommended dosages, which may include once-daily administration.
Rhone-Poulenc Taxotere, Campto Propel Oncology Sales To 39% Growth
Sales of Rhone-Poulenc's Taxotere (docetaxel) jumped 40.9% (excluding the impact of exchange rates) to $116 mil. in the second quarter, leading the firm's oncology revenues.